Sensei Biotherapeutics: Funding, Investors & Team (Sep 2026)
Sensei Biotherapeutics is a clinical-stage biotechnology company specializing in the field of next-generation cancer immunotherapies. The company developing novel biologics therapies targeting key components of the immune system for the treatment of cancers of unmet need. They are also focused on the discovery, development, and delivery of medicines that alter the treatment landscape and contributing value to patients and society. Sensei Biotherapeutics using its proprietary drug discovery platform to study and understand the tumor microenvironment and identify a new class of cancer immunotherapies that act through new biology and differentiated mechanisms. It brings together scientific leaders in biology, immunology, and oncology along with a highly experienced management team and scientific advisors. The company's platform, ImmunoPhage enables the generation of immune-activating agents that fully engage activation of both the innate and adaptive immune systems. Sensei Biotherapeutics is headquartered in Gaithersburg, Maryland with an office in Boston, MA, USA.
Sensei Biotherapeutics has raised $30.0M across 1 funding round on record, the most recent a Series B of $30.0M announced in Jan 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Sensei Biotherapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2021.
Sensei Biotherapeutics Funding Rounds
Sensei Biotherapeutics Founders and Leadership Team
Contact details for the Sensei Biotherapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Sensei Biotherapeutics Funding Compared to Other Biotechnology Startups
Sensei Biotherapeutics' latest round of $30.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Sensei Biotherapeutics in Biotechnology and Gaithersburg
Companies Similar to Sensei Biotherapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Sensei Biotherapeutics Funding FAQs
What does Sensei Biotherapeutics do?
Sensei Biotherapeutics is a clinical-stage biotechnology company specializing in the field of next-generation cancer immunotherapies. The company developing novel biologics therapies targeting key components of the immune system for the treatment of cancers of unmet need. They are also focused on the discovery, development, and delivery of medicines that alter the treatment landscape and contributing value to patients and society. Sensei Biotherapeutics using its proprietary drug discovery platform to study and understand the tumor microenvironment and identify a new class of cancer immunotherapies that act through new biology and differentiated mechanisms. It brings together scientific leaders in biology, immunology, and oncology along with a highly experienced management team and scientific advisors. The company's platform, ImmunoPhage enables the generation of immune-activating agents that fully engage activation of both the innate and adaptive immune systems. Sensei Biotherapeutics is headquartered in Gaithersburg, Maryland with an office in Boston, MA, USA.
How much funding has Sensei Biotherapeutics raised?
Sensei Biotherapeutics has raised $30.0M across 1 round on record. The most recent is a Series B of $30.0M announced in Jan 2021.
When did Sensei Biotherapeutics last raise funding?
Sensei Biotherapeutics' most recent funding round on record is a Series B of $30.0M, announced in Jan 2021.
Who is the CEO of Sensei Biotherapeutics?
John Celebi is listed as CEO at Sensei Biotherapeutics.
Where is Sensei Biotherapeutics headquartered?
Sensei Biotherapeutics is based in Gaithersburg, Maryland, United States.
How many employees does Sensei Biotherapeutics have?
Sensei Biotherapeutics is in the 11-50 employee band.
How does Sensei Biotherapeutics' funding compare to other Biotechnology startups?
Sensei Biotherapeutics' latest round of $30.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Sensei Biotherapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Sensei Biotherapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.